July 23, 2014 6:14 PM ET

Biotechnology

Company Overview of Selecta Biosciences, Inc.

Company Overview

Selecta Biosciences, Inc., a biopharmaceutical company, discovers and develops nanoparticle immunomodulatory drugs and vaccines for the treatment and prevention of human diseases. Its products are designed to deliver bioactive molecules to specific immune cells in the body. The company’s immunomodulatory nanoparticle platform technology enables interaction with the immune system to treat and prevent various diseases, as well as enables the rational design of targeted immunomodulatory nanoparticles that induce or modify cellular and/or humoral immune responses for therapeutic and prophylactic indications. Selecta Biosciences, Inc. has a strategic collaboration with Sanofi. The company was fou...

480 Arsenal Street

Building One

Watertown, MA 02472

United States

Founded in 2007

Phone:

617-923-1400

Fax:

617-924-3454

Key Executives for Selecta Biosciences, Inc.

Chief Executive Officer
Age: 61
Co-Founder and Co-Chair of the Scientific Advisory Board
Co-Founder
Age: 65
Vice President of Finance
Senior Vice President of Pharmaceutical Research
Compensation as of Fiscal Year 2014.

Selecta Biosciences, Inc. Key Developments

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

Selecta Biosciences, Inc. provided an update on the company's product development pipeline, revealing its focus on immune tolerance applications of its proprietary Synthetic Vaccine Particle (SVP) platform. The company announced a new product candidate for its pipeline of tolerogenic immuno therapies: SEL-212 will be the first non-immunogenic treatment for refractory and tophaceous gout. Selecta is now developing products for three applications of antigen-specific tolerance, the inhibition of immunogenicity for biologic therapies, treatment of allergies, and treatment of autoimmune diseases. While the company is focused to accelerate product opportunities in immune tolerance in the near-term, Selecta continues to advance its key SVP immune activation programs, with a grant of $1.25 million from The Bill and Melinda Gates Foundation for malaria vaccines and an award of $8.1 million from the National Institutes of Health (NIH) for Selecta's nicotine vaccine for smoking cessation and relapse prevention. Selecta's latest immune tolerance SVP compound is SEL-212, a novel drug candidate for refractory and tophaceous gout. SEL-212 is designed to be the first non-immunogenic version of uricase, addressing the undesired immunogenicity that has been observed in more than 90% of patients treated with a marketed version of uricase. Treatment-related immunogenicity can lead to a loss of efficacy and severe allergic responses. Through an exclusive license to pegsiticase, Selecta is applying its immunomodulatory SVP platform to dramatically reduce the risk of immunogenicity of other uricase products.

Selecta Biosciences, Inc. Announces Pre-Clinical Study of SEL-201 as an Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

Selecta Biosciences, Inc. announced that data from a pre-clinical proof of concept study in Factor VIII-deficient mice were presented in a poster presentation at the 2013 American Society for Hematology (ASH) International Conference in New Orleans. SEL-201 demonstrated the ability to induce immune tolerance in a model of hemophilia A, showing that SEL-201 has the potential to serve as an adjunct therapy to avoid harmful neutralizing antibody response to Factor VIII treatment severely affecting hemophilia A patients. Researchers at USU demonstrated that Selecta's SEL-201 nanoparticles added onto standard Factor VIII treatment prevented the formation of neutralizing antibodies and led to durable tolerance without affecting the immune response to other antigens. Specifically, SEL-201 conferred antigen-specific and lasting immune tolerance for at least 166 days after the last treatment, while untreated animals developed high levels of neutralizing antibodies. SEL-201 was found to be effective when administering the treatment concomitantly or after priming with FVIII. Selecta Biosciences is working to translate the findings to other approved biologic drugs where undesired immune responses, such as neutralizing antibodies, anaphylaxis and injection site reactions, are major complications.

Selecta Biosciences, Inc. and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies for up to Three Allergy Indications Based on Selecta's Synthetic Vaccine Particle Technology

Selecta Biosciences, Inc. announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the agreement, Sanofi obtains an exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies each to a specific food or aeroallergen. The products resulting from this collaboration will leverage Selecta's proprietary Synthetic Vaccine Particle (SVP(TM)) platform which has unique capabilities to engineer nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens. Under the terms of the agreement Selecta is eligible to receive several pre-clinical, clinical, regulatory and sales milestones totaling $300 million per allergen indication for up to three immunotherapy candidates contemplated by this collaboration. Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for each commercialized immunotherapy. As part of the research alliance, Sanofi will work together with Selecta to design antigen-specific immunotherapies that meet unmet needs as defined by Sanofi for applications where Selecta's technology can offer a new therapeutic approach for life-threatening and other severe allergies. Under the terms of the agreement, Sanofi will have access to Selecta's proprietary Synthetic Vaccine Particle (SVP(TM)) platform that is designed to create robust antigen-specific immune responses for superior immunotherapy effectiveness. This collaboration is aligned with Sanofi's strategic focus areas in immunology and leverages Sanofi's Boston-based research and development capabilities.

Similar Private Companies By Industry

Company Name Region
Prexa Pharmaceuticals, Inc. United States
DNA Plant Technology Corp United States
Cardiac Support Systems, Inc. United States
CMD Bioscience LLC United States
Sequella, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 15, 2014
--
Private Placement
April 7, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Selecta Biosciences, Inc., please visit www.selectabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.